3-Month formulation of goserelin acetate ('Zoladex' 10.8-mg Depot) in advanced prostate cancer: Results from an Italian, open, multicenter trial

Urologia Internationalis

Volumn 70, Issue 4, 2003, Pages 316-320

  Fontana, D ^a   Mari, Mauro ^a,l   Martinelli, A ^b   Boccafoschi, C ^c   Magno, C ^d   Turriziani, M ^e   Maymone, S S ^f   Cosciani Cunico, S ^g   Zanollo, A ^h   Montagna, G ⁱ   Frongia, M ^j   Jacobellis, U ^k  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b Azienda USL di Cesena   (Italy)

^c C Arrigo Children's Hospital   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e Unita Oper Urologia Presidio O   (Italy)

^f SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h Presidio Ospedaliero di Magenta   (Italy)

ⁱ S EUGENIO HOSPITAL   (Italy)

^j BROTZU HOSPITAL   (Italy)

^k POLICLINICO   (Italy)

^l NONE   (Italy)

more..

Author keywords

Androgen deprivation; Goserelin acetate; Prostate cancer; Prostate specific antigen; Testosterone

Indexed keywords

GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURGERY; CASTRATION; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ENDOCRINE SYSTEM; HORMONAL REGULATION; HOT FLUSH; HUMAN; INJECTION SITE; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OPEN STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RASH; SEX HORMONE DETERMINATION; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TISSUE REACTION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; GOSERELIN; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0037624666     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070142     Document Type: Article

References (14)

1. Huggins C, Hodges CV: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941:1:292-297.
2. Veterans Administration Co-Operative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-1017.
3. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-508.
4. Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA Jr, Caplan RJ, Kennealey GT: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomised trial. Urology 1995;46:220-226.
5. Citrin DL, Resnick MI, Guinan P, al-Bussam N, Scott M, Gau TC, Kennealey GT: A comparison of Zoladex and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial. Prostate 1991;18:139-146.
6. Waymont B, Lynch TH, Dunn JA, Emtage LA, Arkell DG, Wallace DM, Blackledge GR: Phase III randomised study of Zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992;69:614-620.
7. Brogden RN, Faulds D: Goserelin. A review of this pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs Aging 1995;6:324-343.
8. Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seldmon EJ, Kennealey GT: Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1992; 1:323-329.
9. Dijkman GA, Debruyne FM, Fernandez del Moral P, Plasman JW, Hoefakker JW, Idema JG, Sykes M: A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group. Eur Urol 1995;27:43-46.
10. Fernandez del Moral P, Dijkman GA, Debruyne FM, Witjes WP, Kolvenbag GJ: Three-month depot of goserelin acetate: Clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology 1996; 48:894-900.
11. Debruyne FM, Dijkman GA, Lee DC, Witjes WP, del Moral F, Karthaus HF, van der Mejden AP, Plasman JW, Pull HC, Kums JJ, Idema JG, Hoefakker JW, Heijbroek RP, Kil PJ, Khoe GS: A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: Results of studies in prostate cancer. J Urol 1996;155:1352-1354.
12. Sarosdy MF, Schellhammer PF, Soloway MS, Vogelzang NJ, Crawford ED, Presti J, Chodak GW, Mitchell P, Porter L: Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999;83:801-806.
13. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ: Randomised open labelled comparative study of the efficacy, safety and tolerability of leuprolin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 1996; 30:7-14.
14. Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB, Stein B: Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 1996;18:647-657.